Bob Ai

Bob focuses on Sino-U.S. cross-border banking, strategic consulting services and investor relations. He joined the firm in 2016.

Prior to joining the firm, Bob was Managing Director, Senior Biotech Analyst at WallachBeth Capital. Before that, he was the CFO of Aoxing Pharmaceuticals, a NYSE listed Chinese specialty pharmaceutical company. He has also served as Principal in the crossover life science private equity firm Merlin Nexus and was Senior Equity Analyst at asset management firms Bennett Lawrence and Merlin Biomed Group.

Bob received his Ph.D. and MBA degrees from Penn State University and did postdoctoral training at the University of Pennsylvania. He has published eight articles in peer-reviewed scientific journals and also won the prestigious Ray Wu scholarship for outstanding Chinese student to study abroad. Bob holds Series 7, 63, 79, 86, and 87 securities licenses.